A 3‐year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

This small study (n=81) found use of an early multidisciplinary proactive therapeutic drug monitoring programme to guide dose adjustment of infliximab for IBD was associated with reduced risk of treatment failure v empirical dosing (HR 0.51; 95% CI 0.27-0.92; p=0.037).

British Journal of Clinical Pharmacology